Conference Call with PI Industries Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Agrochemicals company PI Industries announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, the company reported revenue of Rs 15,652 million, an increase of 13.77% QoQ from Rs 13,757 million in Q3FY26, and a decline of 12.42% YoY compared to Rs 17,871 million in Q4FY25. For the full year FY26, consolidated revenue stood at Rs 67,137 million, representing a decline of 15.84% YoY from Rs 79,778 million in FY25. Total Income: Total income for Q4FY26 was Rs 16,408 million, up 13.75% QoQ from Rs 14,424 million in Q3FY26 and down 11.81% YoY from Rs 18,605 million in Q4FY25. For the full year FY26, total income reached Rs 70,244 million compared to Rs 83,220 million in FY25. Net Profit After Tax (PAT): The company recorded a PAT of Rs 2,002 million in Q4FY26, a decrease of 35.69% QoQ from Rs 3,113 million in Q3FY26 and a decrease of 39.43% YoY from Rs 3,305 million in Q4FY25. For the full year FY26, PAT stood at Rs 13,208 million, marking a decline of 20.44% YoY compared to Rs 16,602 million in FY25. Earnings Per Share (EPS): Basic EPS for Q4FY26 was Rs 13.20, compared to Rs 20.52 in Q3FY26 and Rs 21.79 in Q4FY25. Annual Basic EPS for FY26 was Rs 87.06 compared to Rs 109.44 in FY25. Standalone Financial Highlights: Revenue from Operations: Revenue for Q4FY26 was Rs 13,914 million, up 9.59% QoQ from Rs 12,696 million in Q3FY26 and down 15.58% YoY from Rs 16,482 million in Q4FY25. Annual standalone revenue for FY26 stood at Rs 61,827 million compared to Rs 75,712 million in FY25. Net Profit After Tax (PAT): PAT for Q4FY26 was Rs 1,978 million, down 29.76% QoQ from Rs 2,816 million in Q3FY26 and down 48.73% YoY from Rs 3,858 million in Q4FY25. Annual standalone PAT for FY26 reached Rs 14,348 million against Rs 18,665 million in FY25. Total Comprehensive Income: Total comprehensive income for the year FY26 was Rs 12,935 million compared to Rs 18,456 million in FY25. Business Highlights: Segment Performance (Consolidated): Agro chemicals: This segment contributed Rs 64,168 million to the total revenue for FY26, down from Rs 77,650 million in FY25. Segment results (Profit before tax) for FY26 were Rs 17,975 million. Pharma: This segment contributed Rs 3,005 million to the total revenue for FY26, up from Rs 2,151 million in FY25. The segment reported a loss before tax of Rs 2,744 million for the year. Dividend: The Board of Directors recommended a final dividend of Rs 10/- per equity share (1000%) for FY26. Combined with the interim dividend of Rs 5/- paid earlier, the total dividend for the year is Rs 15/- per equity share of face value Re 1/- each. Qualified Institutional Placement (QIP) Utilization: The company raised Rs 20,000 million through QIP in September 2020. As of FY26, the entire net proceeds of Rs 19,750 million have been fully utilized, with Rs 18,419 million invested in subsidiaries and Rs 1,331 million used for capital expenditure. Exceptional Items: The company recognized a provision for impairment of its investment in PI Health Sciences Limited (PIHS) amounting to Rs 1,100 million due to business losses. An incremental liability of Rs 17 million was recognized in Q4FY26 (totaling Rs 223 million for FY26) due to the reassessment of employee benefit obligations following the notification of new Labour Codes. Management & Personnel Changes: Dr. Marco Busch was designated as Senior Management Personnel effective May 19, 2026. Mr. Rajnish Sarna resigned as Joint Managing Director to focus on health recovery but will continue as a Non-Executive, Non-Independent Director effective May 19, 2026. Dr. Atul Kumar Gupta was appointed as an Additional Director and Whole-time Director for a term of three years effective May 19, 2026. Result PDF
Agrochemicals company PI Industries announced Q3FY26 results Total Income: Rs 13,757 million against Rs 19,008 million during Q3FY25, change -28%. EBITDA: Rs 3,027 million against Rs 5,122 million during Q3FY25, change -41%. EBITDA Margin: 22% for Q3FY26. PAT: Rs 3,113 million against Rs 3,727 million during Q3FY25, change -16%. The company saw a ~32% decline in Agchem Exports (Volume down ~ 29 %) in line with the customer delivery schedule. Pharma revenue contracted by 6% YoY due to the deferment of supply schedules to Q4FY26. Pharma revenue contributes ~5% of the export revenue. Overheads increase, comprising the strategic development of new businesses and the promotion of new products (6%), offset by effective cost control in existing businesses. The Board has approved an interim dividend for FY25-26 of Rs 5.00 per share. Result PDF
Conference Call with PI Industries Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.